[A19-82] Fremanezumab (migraine) - Addendum to Commission A19-44
Last updated 07.11.2019
Project no.:
A19-82
Commission:
Commission awarded on 24.09.2019 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Head and nerves
Indication:
Migraine prophylaxis in adult patients with at least 4 migraine days per month
Result of dossier assessment:
Based on subsequently submitted analyses, there is now an indication of non-quantifiable added benefit
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A19-44 | Fremanezumab (prophylaxis of migraine) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2019-11-07 A G-BA decision was published.